智通财经网·2025-12-23 02:08Core Viewpoint - Rongchang Biopharmaceutical (09995) has seen a stock increase of over 3%, currently at 78.8 HKD, with a trading volume of 98.38 million HKD, following the release of promising clinical trial data for its PD-1/VEGF bispecific antibody RC148 in treating non-small cell lung cancer [1] Group 1: Clinical Research and Development - The research report from Huaxi Securities highlights that the clinical data for RC148, both as a monotherapy and in combination therapy, demonstrates significant clinical efficacy and manageable safety, achieving a dual-pathway breakthrough [1] - Based on early data from the RC148-C001 study, the drug has received Breakthrough Therapy Designation (BTD) in China for treating locally advanced or metastatic non-small cell lung cancer that has failed prior PD-1/PD-L1 inhibitors and platinum-based chemotherapy [1] - The company is actively advancing its clinical trials, with the Phase II trial for RC148 in combination therapy for first-line non-small cell lung cancer having completed patient enrollment, and plans to initiate a Phase III clinical study [1]